Effect of Receiving Intravenous Vitamin C on Dyslipidemia in Patients Undergoing Hemodialysis

Background: Dyslipidemia is one of the major causes of the production and progression of atherosclerosis in hemodialysis patients. Vitamin C is able to improve dyslipidemia by reducing an oxidative stress. Aim: The aim of this study was to evaluate the effect of vitamin C supplementation on dyslipidemia in hemodialysis patients. Methods: In a randomized, double-blind clinical trial, 160 patients with chronic renal failure were studied. They were divided into three groups (intervention, control and witness). In an intervention group, 250 mg from vitamin C was injected, three times weakly at the end of each dialysis session via the intravenous route, for 8 weeks. In the control group same amount of placebo saline was injected and in the witness group no intervention was performed. Required laboratory parameters including serum total cholestrole, triglyserid and HDL were measured at the beginning and end of the intervention. In order to analyze the data, SPSS statistical software was used, and test Chi square and ANOVA were performed. P value less than 0.05 is considered statistical significance. Results: No significant differences were observed in the serum levels of cholesterol, triglyceride and HDL between groups before and after the intervention. Conclusion: The results of this study demonstrated that 250 mg intravenous vitamin C did not change serum levels of cholesterol, triglyceride and HDL.